212 related articles for article (PubMed ID: 24911795)
1. Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma.
du Rusquec P; Saint-Jean M; Brocard A; Peuvrel L; Khammari A; Quéreux G; Dréno B
J Immunother; 2014; 37(6):348-50. PubMed ID: 24911795
[TBL] [Abstract][Full Text] [Related]
2. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).
Akhtari M; Waller EK; Jaye DL; Lawson DH; Ibrahim R; Papadopoulos NE; Arellano ML
J Immunother; 2009 Apr; 32(3):322-4. PubMed ID: 19242368
[TBL] [Abstract][Full Text] [Related]
3. Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiency.
Bakacs T; Mehrishi JN
Immunobiology; 2015 May; 220(5):624-5. PubMed ID: 25638260
[TBL] [Abstract][Full Text] [Related]
4. Delayed dermatologic hypersensitivity reaction secondary to ipilimumab.
Ludlow SP; Kay N
J Immunother; 2015 May; 38(4):165-6. PubMed ID: 25839442
[TBL] [Abstract][Full Text] [Related]
5. Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma.
Crosson JN; Laird PW; Debiec M; Bergstrom CS; Lawson DH; Yeh S
J Immunother; 2015; 38(2):80-4. PubMed ID: 25658618
[TBL] [Abstract][Full Text] [Related]
6. [Orbital myositis associated with ipilimumab].
Lecouflet M; Verschoore M; Giard C; Gohier P; Le Corre Y; Milea D; Martin L
Ann Dermatol Venereol; 2013; 140(6-7):448-51. PubMed ID: 23773743
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab targeting CD28-CTLA-4 axis: new hope in the treatment of melanoma.
Lens M; Testori A; Ferucci PF
Curr Top Med Chem; 2012; 12(1):61-6. PubMed ID: 22196270
[TBL] [Abstract][Full Text] [Related]
8. Ipilimumab (Yervoy) and the TGN1412 catastrophe.
Bakacs T; Mehrishi JN; Moss RW
Immunobiology; 2012 Jun; 217(6):583-9. PubMed ID: 21821307
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab-induced Guillain-Barré Syndrome Presenting as Dysautonomia: An Unusual Presentation of a Rare Complication of Immunotherapy.
Kelly Wu W; Broman KK; Brownie ER; Kauffmann RM
J Immunother; 2017 Jun; 40(5):196-199. PubMed ID: 28452849
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for malignant melanoma.
Zeiser R; Schnitzler M; Andrlova H; Hellige T; Meiss F
Curr Stem Cell Res Ther; 2012 May; 7(3):217-28. PubMed ID: 22329580
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
12. Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma.
Danlos FX; Pagès C; Roux J; Jebali M; Gornet JM; Bagot M; Lebbé C
Melanoma Res; 2015 Apr; 25(2):178-9. PubMed ID: 25464388
[TBL] [Abstract][Full Text] [Related]
13. Ipilimumab in advanced melanoma: reports of long-lasting responses.
Farolfi A; Ridolfi L; Guidoboni M; Nicoletti SV; Piciucchi S; Valmorri L; Costantini M; Scarpi E; Amadori D; Ridolfi R
Melanoma Res; 2012 Jun; 22(3):263-70. PubMed ID: 22516968
[TBL] [Abstract][Full Text] [Related]
14. A case report of orbital inflammatory syndrome secondary to ipilimumab.
Henderson AD; Thomas DA
Ophthalmic Plast Reconstr Surg; 2015; 31(3):e68-70. PubMed ID: 24814274
[TBL] [Abstract][Full Text] [Related]
15. Update on immunotherapy in melanoma.
Green J; Ariyan C
Surg Oncol Clin N Am; 2015 Apr; 24(2):337-46. PubMed ID: 25769716
[TBL] [Abstract][Full Text] [Related]
16. Melanoma immunotherapy: historical precedents, recent successes and future prospects.
Raaijmakers MI; Rozati S; Goldinger SM; Widmer DS; Dummer R; Levesque MP
Immunotherapy; 2013 Feb; 5(2):169-82. PubMed ID: 23413908
[TBL] [Abstract][Full Text] [Related]
17. Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab.
Bjoern J; Iversen TZ; Nitschke NJ; Andersen MH; Svane IM
Cytotherapy; 2016 Aug; 18(8):1043-1055. PubMed ID: 27378345
[TBL] [Abstract][Full Text] [Related]
18. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.
Juszczak A; Gupta A; Karavitaki N; Middleton MR; Grossman AB
Eur J Endocrinol; 2012 Jul; 167(1):1-5. PubMed ID: 22495490
[TBL] [Abstract][Full Text] [Related]
19. An Autoimmune Haemolytic Anaemia Secondary to Ipilimumab Treatment.
Ramos B; Gastal G; Rovere RK
Klin Onkol; 2017; 30(2):128-130. PubMed ID: 28397508
[TBL] [Abstract][Full Text] [Related]
20. [Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma].
Lotem M; Merims S; Frank S; Ospovat I; Peretz T
Harefuah; 2012 Oct; 151(10):585-8, 604. PubMed ID: 23316667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
